Parexel lowered its fiscal-year revenue projections by about 2% despite posting modest growth in the last quarter, working through a sizable restructuring program designed to boost profits.
CRO giant Parexel has inked a new pact with the Optum Life Sciences unit of the nation's largest insurer, UnitedHealth Group, to help lower costs in postapproval studies.
CRO Parexel International is buying a 120-employee consulting firm headquartered in Boston, focusing on market access and commercialization.
Parexel International, working through a broad restructuring, said it upgraded its clinical trial management technology to make it scalable for study sponsors of all sizes.
Parexel International, in the midst of sweeping cost cuts, said it has further integrated technology into its drug development services, creating a data-informed process designed to speed up timelines and save money.
Parexel International, in the process of shedding about 850 jobs, saw its net income dip in the fiscal first quarter, dimming its expectations for the full year.
Parexel International, slashing jobs after a rough run, posted some modest revenue gains in its fiscal fourth quarter, and now the CRO is looking to build some momentum with a jump in new business.
Parexel is expanding its efforts in so-called model-based drug development, using data analytics to flesh out a drug's potential safety, efficacy and interactions before beginning a clinical trial.
CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.
CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.